Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Januar 2021 07:00 ET | Quelle: Clene Inc.

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis

Resulting patent to cover methods of using Clene’s lead candidate CNM-Au8, now in Phase 2 and 3 trials for Multiple Sclerosis (MS) and Amyotrophic lateral sclerosis (ALS)Latest patent allowance adds...
30. Dezember 2020 17:38 ET | Quelle: Clene Nanomedicine

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update

Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020 Clinical pipeline includes an ongoing Phase 3...
10. Dezember 2020 12:10 ET | Quelle: Clene Nanomedicine

Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MND

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2...

Vorherige Seite